Anthony Olszanski
Vice Chair, Clinical Research, Department of Hematology/Oncology · Temple University Hospital
Credentials: · · ·
History
PresentClinical Research · Temple University Hospital
- Present
Melanoma and Skin Cancer Program · Temple University Hospital
- Present
Section of Solid Tumor Oncology Division · Temple University Hospital
- 1999–2001
Medical Oncology
- 1996–1999
Internal Medicine
- 1992–1996
Research
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Cell · 2017 · 1,205 citations
Management of Immunotherapy-Related Toxicities, Version 1.2019
Journal of the National Comprehensive Cancer Network · 2019 · 447 citations
Review · Journal of the National Comprehensive Cancer Network · 2022 · 415 citations
- JT
13 papers
10 papers
10 papers
9 papers
- JL
9 papers
9 papers
9 papers
8 papers
Grants
- 2023–2026
National Cancer Institute · R21
PI · $472.4K · Research Inst of Fox Chase Can Ctr
- 2021–2023
A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib
National Cancer Institute · R01
PI · $726.6K · Wistar Institute
Clinical trials
- 2022–2027
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Principal investigator · Recruiting · Early phase 1
Fox Chase Cancer Center
- 2017–2023
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Principal investigator · Completed · Phase 1, Phase 2
Intensity Therapeutics, Inc.
- 2016–2018
Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer
Principal investigator · Completed
Fox Chase Cancer Center
- 2015–2020
Principal investigator · Completed · Phase 1
Fox Chase Cancer Center